DifGen Pharmaceuticals Gains FDA Clearance for Clinical Development of Advanced Breast Cancer Treatment

DifGen Pharmaceuticals Cleared by FDA to Commence Clinical Trials for Novel Breast Cancer Treatment

Miramar, Fla. – DifGen Pharmaceuticals has been granted clearance by the U.S. Food and Drug Administration (FDA) to proceed with clinical development of DFGN-101, a drug intended for the treatment of advanced or metastatic breast cancer in women.

The treatment candidate, DFGN-101, is designed for administration as a single intramuscular injection. This contrasts with the current reference product, which requires two separate injections per treatment visit. If approved, DFGN-101 could offer a streamlined patient experience by reducing the number of required injections.

The FDA's decision, communicated via a "study may proceed" letter, allows DifGen to move forward with preclinical toxicology studies in rats and rabbits, followed by a Phase 1 pharmacokinetic study. Notably, the agency has indicated that a clinical endpoint efficacy study will not be required for this development pathway. This position was reportedly influenced by DifGen's Chemistry, Manufacturing, and Controls (CMC) data package and initial pilot pharmacokinetic study results, which demonstrated a comparable profile to the existing treatment.

This clearance signifies DifGen Pharmaceuticals' capabilities in formulating complex drugs and establishing efficient development pathways for technically challenging programs. The company focuses on developing complex generic pharmaceuticals and managing supply chains to ensure access to medicines.